IA
ZNTL icon

IFP Advisors’s Zentalis Pharmaceuticals ZNTL Stock Holding History

IFP Advisors’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-24
Closed -$36 – 5057
2025
Q3 		$36 Sell
24
-11
-31% -$16 ﹤0.01% 4699
2025
Q2 		$40 Buy
+35
New +$46 ﹤0.01% 4813
2025
Q1 		– Sell
-23
Closed -$70 – 4672
2024
Q4 		$70 Buy
+23
New +$75 ﹤0.01% 4156
2022
Q4 		– Sell
-1,382
Closed -$42K – 4870
2022
Q3 		$42K Buy
1,382
+14
+1% +$383 ﹤0.01% 2513
2022
Q2 		$41K Hold
1,368
– – ﹤0.01% 2307
2022
Q1 		$41K Buy
1,368
+146
+12% +$7.88K ﹤0.01% 2307
2021
Q4 		$102K Buy
+1,222
New +$94.6K ﹤0.01% 1256

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

IFP Advisors's ZNTL Position: Q4 2025 in Review

IFP Advisors sold out of Zentalis Pharmaceuticals (ZNTL) in Q4 2025, closing a stake of 24 shares — an estimated $36 sold.

IFP Advisors first reported a position in ZNTL in Q4 2021 and held it in 7 quarters. The position peaked at $102K in Q4 2021. 86 funds tracked by Wall St. Rank hold ZNTL as of Q4 2025.

  • IFP Advisors reported no remaining Zentalis Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • IFP Advisors sold 24 Zentalis Pharmaceuticals shares in Q4 2025, an estimated $36.
  • IFP Advisors first reported a position in Zentalis Pharmaceuticals in Q4 2021 and held it in 7 quarters.
  • IFP Advisors's Zentalis Pharmaceuticals position peaked at $102K in Q4 2021.
  • 86 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q4 2025.

Based on IFP Advisors's 13F filing for Q4 2025, filed 6 Feb 2026.